Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

BACKGROUND: Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Lancet
Main Authors: Williams, Bryan, MacDonald, Thomas M, Morant, Steve, Webb, David J, Sever, Peter, McInnes, Gordon, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Salsbury, Jackie, Mackenzie, Isla, Padmanabhan, Sandosh, Brown, Morris J
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier 2015
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4655321/
https://ncbi.nlm.nih.gov/pubmed/26414968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00257-3
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים